Mirum Pharmaceuticals
Mirum Pharmaceuticals Inc is an American biopharmaceutical company focused on developing and commercializing therapies for rare cholestatic liver diseases. The company offers commercial products including Livmarli for Alagille syndrome and progressive familial intrahepatic cholestasis, alongside Chenodal for cerebrotendinous xanthomatosis. Principal revenues are generated through commercial sales of its specialty prescription drugs to specialty pharmacies and international distributors. Core end markets consist of pediatric hepatology centers, rare disease clinics, and specialized tertiary hospitals worldwide. Mirum Pharmaceuticals holds a prominent position within the rare disease biopharmaceutical sector through its targeted oral liver disease pipeline. The company is headquartered in Foster City, California, and its common stock is traded on the Nasdaq Global Select Market.
8 of the funds FundTelligence covers report a position in Mirum Pharmaceuticals.
- Legal name
- Mirum Pharmaceuticals Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 8
Funds holding Mirum Pharmaceuticals
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 1.64 % (full portfolio disclosed, September 2026)
- Handelsbanken Helse Tema — Handelsbanken · 0.55 % (full portfolio disclosed, October 2026)
- Handelsbanken Amerika SMB Tema — Handelsbanken · 0.54 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.39 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.05 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.04 % (partially disclosed portfolio, June 2026)
- DNB Global Enhanced Small Cap — DNB · 0.04 % (full portfolio disclosed, September 2026)
- Mercer Global Small Cap Equity Fund — Mercer · 0.03 % (full portfolio disclosed, December 2025)